Rapport Therapeutics公布局灶性癫痫发作试验积极结果

投资观察
Sep 08, 2025

9月8日 - Rapport Therapeutics Inc.宣布其RAP-219药物在局灶性癫痫发作患者中的2A期临床试验取得积极的顶线结果。

试验达到主要终点,RAP-219耐受性良好。

患者癫痫发作减少77.8%,24%的患者实现无癫痫发作状态。

RAP-219耐受性良好,不良事件轻微。

公司计划在2025年第四季度与美国食品药品监督管理局(FDA)举行2期试验结束会议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10